Aysehan Akinci, Ismail Dundar, Dilvin Celik Ates

The relationship between autoimmunity and HbA1c in type 1

Indicators of increased risk for type 1 diabetes (T1DM) are specific antibodies that are mainly immune markers. Islet cell antibody (ICA), insulin autoantibody (IAA), glutamic acid decarboxylase enzyme antibody (GADA) and HgA1c are also used in the diagnosis and follow-up of patients with type 1 diabetes mellitus. ICA, IAA, GADA, HbA1c were checked at the time of diagnosis and at 6-month intervals in pediatric patients monitored with T1DM. Decreased ICA, GADA and HbA1c levels were evaluated as good blood glucose control and good clinical response. Patients aged ≤5 years had a higher rate of IAA and patients aged >5 years had a higher rate of ICA. Antibody selection according to age during diabetes screening was found to be significant in terms of cost.

PDF

___

1. Ishii M, Hasegavva G, Fukui M, et al. Clinical and genetik characteristic of diabetic patients with high-titer(>10000 U/ml) of antibodies to glutamic acid decarboxylase. Immunol Lett. 2005;99:180-5.
2. Kupila A, Keskinen P, Simell T, et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes. 2002;51:646-51.
3. Borg H, Marcus C, Sjöblad S, et al. Insulin autoantibodies are of less value compared with islet antibodies in the clinical diagnosis of autoimmune type 1 diabetes in children older than 3 yr of age. Pediatr Diabetes. 2002;3:149- 54.
4. Chang YH, Shiau MY, Tsai ST, et al. Autoantibodies against IA-2, GAD, and topoisomerase II in type 1 diabetic patients. Biochem Biophys Res Commun. 2004;320:802-9.
5. Isermann B, Ritsal R, Zorn M, et al. Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes. 2007;115:483-90.
6. Lifshitz F. Pediatric Endocrinology. Fourth edition. 2003;28:683-720.
7. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750-4.
8. Atkinson MA, McLaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428-36.
9. Stene LC, Magnus P, Lie RT, et al. The Norwegian childhood Diabetes Study Group. Birth weight and childhood onset type 1 diabetes: population based cohort study. BMJ. 2001;322:889-92.
10. Bosi E, Sarugeri E. Advances and controversies in etiopathogenesis of type 1 (insulin- dependent) diabetes mellitus. J Pediatr Endocrinol Metab. 1998;2:293-305.
11. Dahlquist G.The etiology of type 1 diabetes. An epidemiological perspective. Açta Paediatr. 1998;425:5-10.
12. Colman PG, Steele C, Couper JJ, et al. Islet autoimmunity in infants with a type 1 diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia. 2000;43:203-9.
13. Maugendre D, Sonnet E, Derrien C, et al. Combined analysis of long-term anti-beta-cell humoral reactivity in type 1 diabetes with and without thyroid disease. Diabetes Metab. 1999;25:28-33.
14. WasserfalI CH and Atkinson MA. Autoimmunity Revievvs. 2006;6:424-8.
15. Arnold JG, McGovvan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1c levels. J American Board. 2007;20:93-6.
16. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
17. The Writing team for the diabetes control and complications trial/ epidemiology of diabetes interventions and complications research group. Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus. JAMA. 2002;287:2563-9.
18. Redondo MJ, Connor CG, Ruedy KJ, et al. Pediatric Diabetes Consortium. Pediatric diabetes consortium type 1 diabetes new onset (NeOn) study: factors associated with HbA1c levels one year after diagnosis. Pediatric Diabetes. 2014;15:294-302.
19. Hoeldtke RD, Bryner KD, Horvath GG, et al. Antibodies to GAD and glycemic control in recent- onset IDDM. Diabetes Care. 1997;20:1900-3.
20. Feeney SJ, Myers MA, Mackay İR, et al. Evaluation of ICA512As in combination with other islet celi autoa ntibodies at the onset of IDDM. Diabetes Care. 1997;20:1403-7.
21. Zimmet PZ, Rowley MJ, Mackay IR, et al. The ethnic distributionof antibodies to glutamic asid decarboxylase: presence and levels of insulin dependent diabetes mellitus in Europid and Asian subject. J. Biabetes Complicat. 1993;7:1-7.
22. Rodacki M, Zajdenverg L, Albernaz MS, et al. Relationship betvveen the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients. Braz J Med Biol Res. 2004;37:1645-50.
23. Beterle C, Lazzarotto F, Fusari A, et al. Pancreatic autoantibodies in Italian patients with newly diagnosed type 1 diabetes mellitus over the age of 20 years. Acta Diabetol. 2006;43:79-3.
24. Yaghootkar H, Abbasi F, Ghaemi N,et al. Type 1 diabetes genetic risk score discriminates between monogenic and Type 1 diabetes in children diagnosed at the age of <5 years in the Iranian population. Diabet Med. 2019;36:1694-702.